Dequalinium analogs

Details Dequalinium analogs Dequalinium analogs

2005-12-13

2005-12-13

Seaman, D. Margaret (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C546S153000, C546S159000

Reexamination Certificate

active

06974871

ABSTRACT:
A composition for protecting human skin from harmful effects of the sun, the composition comprising a topically effective amount of:(a) a first chemical compound that absorbs ultraviolet light sufficiently to reduce significantly the damage to human skin from harmful effects of ultraviolet light; and(b) a second chemical compound having the formula:in-line-formulae description="In-line Formulae" end="lead"?(Q-T)u+X−vin-line-formulae description="In-line Formulae" end="tail"?wherein:Q represents 4-E-2-R3-1-quinolinium;E represents NR1R2, COO R1, OR1, I, Br, Cl, F, or NO3N represents a nitrogen atom;R1and R2independently represent hydrogen or lower alkyl;R3represents E, hydrogen or lower alkyl;T represents hydrogen or a chain comprising m atoms, the atoms in the chain being t carbon atoms and 0 to approximately 0.5t heteroatoms;the minimum value of m is 6;the maximum value of m is 22;X represents an anion; andu and v represent 1, 2, or 3 with the proviso that u=v.

REFERENCES:
patent: 5208011 (1993-05-01), Vaughan
patent: 5914102 (1999-06-01), Fowler et al.
patent: 6090619 (2000-07-01), Weissig et al.
patent: 6133264 (2000-10-01), Oshiro et al.
patent: 6171863 (2001-01-01), Weissig et al.
patent: 2001/0001067 (2001-05-01), Weissig et al.
Qin, et al.; “Inhibition of Protein Kinase Cα by Dequalinium Analogues: Dependence on Linker Length and Geometry,” Journal of Medicinal Chemistry, vol. 43, No. 7, pp. 1413-1417; (2000).
Sullivan, et al.; “Photo-Induced Inactivation of Protein Kinase Cα by Dequalinium Inhibits Motility of Murine Melanoma Cells,” Molecular Pharmacology, vol. 58, No. 4, pp. 729-737; (2000).
Rotenberg, et al.; “Deletion Analysis of Protein Kinase Cα Reveals a Novel Regulatory Segement,” J. Biochem., vol. 124, pp. 756-763; (1998).
Galanakis, et al.; “Synthesis and Quantitative Structure-Activity Relationships of Dequalinium Analogues as K+ channel Blockers :Investigation into the Role of the Substituent at Position 4 of the Quinoline Ring,” J. Med. Chem. 38: 3536-3546 (1995).
Galanakis, et al.; “Synthesis and Quantitative Structure-Activity Relationships of Dequalinium Analogues as K+ channel Blockers. Investigations on the role of the Charged Heterocycle,” J. Med. Chem. 38: 595-606 (1995).
Galanakis, et al.; “Synthesis and Quantitative Structure-Activity Relationship of a Novel Series of Small Conductance Ca2+-Activated K+ Channel Blockers Related to Dequalinium,” J. Med. Chem. 39: 359-370 (1996).
Galanakis, et al.; “synthesis and Pharmacological Testing of Dequalinium Analogues as Blockers of the Apamin-Sensitive Ca2+-Activated K+ Channel: Variation of the Length of the Alkylene chain,” J. Med. Chem. 39: 3592-3595 (1996).
Rotenberg et al., “Photoinduced Inactivation of Protein Kinase C by Dequalinium Identifies the RACK-1-binding Domain as a recognition Site,”J. Biological Chemistry, pp. 2390-2395, 273:4, (1995).
Rotenberg et al., “Inhibition of Rodent Kinase C by the Anticarcinoma Agent Dequalinium1,”Cancer Research, pp. 677-685, 50 (1990).
Cox, “Chemical Structure and Antimicrobial Activity in Two Related Homologous Series of Quaternary Ammonium Compounds,” Chem. Phys. Appl. Surface Active Subst., 1: 79-91 (1967) [Abstract].
Cox, et al., “A Series of Decamethylenebis [(4-substituted amino) quinaldinium] Salts with Potent Antibacterial Properties,” J. Pharm. Pharmacol. 19:155-60 (1967) [Abstract].
Weissig et al., DQAsomes: Structural Requirements for Vesicle Formation, Proceedings of the International Symposium on Controlled Release of Bioactive Materials, 26:519-520 (1999) [Abstract].
Taylor, et al, “Capillary Electrophoresis and Liquid Chromatography in the Analysis of Some Quaternary Ammonium Sales Used in Lozenges as Antibacterial Agents”, Journal of Capillary Electrophoresis, 5:45-50 (1998) [Abstract].
Galanakis et al.; “Abstract: On the Concept of a Bivalent Pharmacophore for SKCa Channel Blockers. Synthesis, Pharmacological Testing, and Radioligand Binding Studies on Mono-, Bis-, and Trisquinolinium Compounds,” Dept. Chemistry, U. of College London, Archiv der Pharmazie, 329(12): pp. 524-528 (1996).
Medline Abstract 19999402168, abstract of Lancet, vol 354 (9180), pp. 723-729, 1999.

Affiliated with

Also associated with

Rating

Dequalinium analogs does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Dequalinium analogs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dequalinium analogs will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3521500